Broadway Wealth Solutions Inc. Buys 484 Shares of IQVIA Holdings Inc. $IQV

Broadway Wealth Solutions Inc. raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 33.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,944 shares of the medical research company’s stock after acquiring an additional 484 shares during the period. Broadway Wealth Solutions Inc.’s holdings in IQVIA were worth $306,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of IQV. American National Bank & Trust bought a new position in IQVIA during the 1st quarter valued at $26,000. Clal Insurance Enterprises Holdings Ltd lifted its stake in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 131 shares in the last quarter. Golden State Wealth Management LLC lifted its stake in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new position in IQVIA during the 1st quarter valued at $33,000. Finally, ST Germain D J Co. Inc. lifted its stake in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 76 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on IQV. Evercore ISI lifted their target price on IQVIA from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 9th. Robert W. Baird lifted their price objective on IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a report on Wednesday, July 23rd. Cowen reissued a “buy” rating on shares of IQVIA in a report on Wednesday, July 23rd. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $195.00 to $225.00 in a report on Tuesday, September 9th. Finally, Mizuho lifted their price objective on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Eighteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $229.64.

IQVIA Stock Up 5.1%

IQV stock opened at $189.96 on Wednesday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $32.29 billion, a PE ratio of 27.49, a PEG ratio of 1.98 and a beta of 1.32. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $237.34. The stock has a 50-day simple moving average of $187.49 and a two-hundred day simple moving average of $167.18.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.